ADVISORY/Cytyc Corporation Chairman and CEO Scheduled to Present at Morgan Stanley Second Annual Global Healthcare Conference.

Business Editors/High-Tech Writers

ADVISORY...Wednesday (May 5)

BOXBOROUGH, Mass.--(BUSINESS WIRE)--April 29, 2004

Cytyc Corporation (Nasdaq: CYTC) today announced that Patrick J. Sullivan, chairman, president, and chief executive officer, is scheduled to present at the Morgan Stanley Second Annual Global Healthcare Unplugged Conference on May 5, 2004, at 4:00 p.m., at the Mandarin Oriental Hotel in Miami, Florida.

A live webcast and recording of the presentation will be available on Cytyc's website, http://ir.cytyc.com, at the conclusion of the business day on May 5, 2004. The recording will be available until May 17, 2004.

Cytyc Corporation is a leading medical device company that designs, develops, manufactures, and markets innovative and clinically effective products primarily focused on women's health. Cytyc products cover a range of women's health applications, including cervical cancer screening, breast cancer risk assessment, and treatment of excessive menstrual bleeding. The ThinPrep(R) System is the most widely used method for cervical cancer screening in the United States. The ThinPrep System consists of the ThinPrep(R) 2000 Processor, ThinPrep(R) 3000 Processor, ThinPrep(R) Imaging System, and related reagents, filters, and other supplies. The ThinPrep System also provides the platform from which the Company has launched its expansion into breast cancer risk assessment with the FirstCyte(R) Breast Test. Cytyc Surgical Products, a wholly owned subsidiary of Cytyc Corporation, manufactures and markets the NovaSure(R) Impedance Controlled Endometrial Ablation System, or the NovaSure(R) System, an innovative endometrial ablation device to treat menorrhagia, or excessive menstrual bleeding.

Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC. Cytyc, ThinPrep, NovaSure, and FirstCyte are registered trademarks of Cytyc Corporation.